Najmeh Ghasemi - Nourdanesh Higher Education Institute, National Institute of Genetic Engineering and Biotechnology (NIGEB)
Najaf Allahyary fard - Nourdanesh Higher Education Institute, National Institute of Genetic Engineering and Biotechnology (NIGEB)

Introduction & Aim: Carcinoma is a malignant epithelial tumor which extends from epithelial cells. Microtubules play an important role in cell division through involve in different stages of mitoses, so it is an important target for development anticancer drugs. In recently decade, new antimicrotubul agents have spread. Recently, developing of tubulin inhibitors has been derived from the agents of Colchicine s position. Accordingly, in this research we focus on the drugs that are linked to colchicine binding site. We studied in this research; 1-AVE8062, 2- BPR0L075, 3- ABT-751, 4- Indibulin, 5- 2-Methoxy-estradiol. All of these drugs have completed several steps of clinical trials, but they are still under investigation.Methods: First, existing drugs and anti-carcinoma developing drugs were extracted from related articles and the Drug Bank database. After reviewing these drugs, 5 candidates were selected for docking. To do docking, we used Molegro Virtual Docker 3.0. The tubulin- colchicine complex with 4O2B code was retrieved from the PDB database and separated Colchicine from tubulin protein by the software. colchicine, tubulin, and selected drugs set put in the minimum energy. We put tubulin and colchicine in the dock software and docking options were done for select the algorithm. It done by using the SE algorithm, and with the template docking method and with the pattern of colchicine docking.Results & Conclusion: Our results showed that BPR0L075 is the best anti-carcinoma ligand in the position of colchicine binding site to tubulin.